Skip to Content
MilliporeSigma

Skip To

L2545

LY225910

≥98% (HPLC)

Synonym(s):

2-[2-(5-Bromo-1H-indol-3-yl)ethyl]-3-[3-(1-methylethoxy )phenyl]-4-(3H)-quinazolinone

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Size/SKUAvailabilityPrice
25 mg
Check Cart for Availability
$366.00

About This Item

Empirical Formula (Hill Notation):
C27H24BrN3O2
CAS Number:
Molecular Weight:
502.40
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352202
MDL number:
Assay:
≥98% (HPLC)
Form:
powder

$366.00


Check Cart for Availability

​
Request a Custom Order
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Quality Segment

assay

≥98% (HPLC)

form

powder

color

off-white

solubility

DMSO: >20 mg/mL

originator

Eli Lilly

storage temp.

2-8°C

SMILES string

CC(C)Oc1cccc(c1)N2C(CCc3c[nH]c4ccc(Br)cc34)=Nc5ccccc5C2=O

InChI

1S/C27H24BrN3O2/c1-17(2)33-21-7-5-6-20(15-21)31-26(30-25-9-4-3-8-22(25)27(31)32)13-10-18-16-29-24-12-11-19(28)14-23(18)24/h3-9,11-12,14-17,29H,10,13H2,1-2H3

InChI key

KUECXUACQOYKNB-UHFFFAOYSA-N

Biochem/physiol Actions

Cholecystokinin is expressed in the gastrointestinal tract and the central nervous system. Cholecystokinin receptor type 2 (CCK2) is a GPCR that is highly expressed in brain and spinal cord. CCK2 is implicated in many brain processes, including mood, anxiety, and pain, through its modulation of GABA neurotransmission.

LY225910 is a potent, selective CCK2 antagonist. LY225910 blocks agonism of CCK2 by CCK-8S, the peptide agonist. LY225910 has been measured in multiple systems, including GABA efflux from cortical cultures, depolarization of spinal cord neurons (via potassium conductance), modulation of excitatory postsynaptic potentials (EPSPs) in nucleus accumbens slices, and enhancement of morphine analgesia.
LY 225910 is a potent, selective CCK2 antagonist.

Features and Benefits

This compound is featured on the Cholecystokinin and Gastrin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
L6670C9749L4420
description

≥98% (HPLC)

description

≥98% (HPLC), powder

description

≥98% (HPLC)

description

≥98% (HPLC)

form

powder

form

powder

form

powder

form

powder

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

100

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

room temp

solubility

DMSO: >20 mg/mL

solubility

DMSO: ≥20 mg/mL

solubility

DMSO: >20 mg/mL

solubility

H2O: >10 mg/mL

color

off-white

color

white to tan

color

off-white to light brown

color

white to off-white


Pictograms

Skull and crossbones

Signal Word

Danger

Hazard Codes

Hazard Classifications

Acute Tox. 3 Oral - Aquatic Chronic 4

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point (°F)

638.6 - 762.1 °F

Flash Point (°C)

337 - 405.6 °C



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library




Questions

Reviews

No rating value

Active Filters